Tillkännagivande • Jun 23
Elite Pharmaceuticals, Inc. to Report Fiscal Year 2026 Results on Jun 29, 2026 Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2026 results on Jun 29, 2026 Tillkännagivande • Jun 18
Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence Study Elite Pharmaceuticals, Inc. reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant generic drug product. IQVIA reported branded and generic product sales for the twelve months ending April 2026 of $840 million. The studies conducted were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two-sequence, crossover bioequivalence studies in normal, healthy, adult, human subjects under fasting conditions. The results indicated that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration. Tillkännagivande • Feb 12
Elite Pharmaceuticals, Inc. to Report Q3, 2026 Results on Feb 17, 2026 Elite Pharmaceuticals, Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026 Tillkännagivande • Nov 10
Elite Pharmaceuticals, Inc. to Report Q2, 2026 Results on Nov 14, 2025 Elite Pharmaceuticals, Inc. announced that they will report Q2, 2026 results on Nov 14, 2025 Tillkännagivande • Aug 09
Elite Pharmaceuticals, Inc. to Report Q1, 2026 Results on Aug 14, 2025 Elite Pharmaceuticals, Inc. announced that they will report Q1, 2026 results on Aug 14, 2025 Tillkännagivande • Jun 23
Elite Pharmaceuticals, Inc. to Report Fiscal Year 2025 Results on Jun 30, 2025 Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2025 results on Jun 30, 2025 Tillkännagivande • Nov 11
Elite Pharmaceuticals, Inc. to Report Q2, 2025 Results on Nov 14, 2024 Elite Pharmaceuticals, Inc. announced that they will report Q2, 2025 results on Nov 14, 2024 Tillkännagivande • Jun 27
Elite Pharmaceuticals, Inc. to Report Q4, 2024 Results on Jul 01, 2024 Elite Pharmaceuticals, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Jul 01, 2024 Tillkännagivande • May 23
Elite Pharmaceuticals Receives Fda Approval for Generic Methotrexate Elite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label. IQVIA reported annual sales of $64.3 million for the twelve months ending March 2024 for the generic market for this product. Tillkännagivande • Feb 09
Elite Pharmaceuticals, Inc. to Report Q3, 2024 Results on Feb 14, 2024 Elite Pharmaceuticals, Inc. announced that they will report Q3, 2024 results on Feb 14, 2024 Tillkännagivande • Dec 26
Elite Pharmaceuticals, Inc. Files ANDA with US FDA to Market Central Nervous System Stimulant Elite Pharmaceuticals, Inc. announced the US Food and Drug Administration's (FDA) acceptance for review of an Abbreviated New Drug Application (ANDA) on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants. Tillkännagivande • Nov 11
Elite Pharmaceuticals, Inc. to Report Q2, 2024 Results on Nov 14, 2023 Elite Pharmaceuticals, Inc. announced that they will report Q2, 2024 results at 4:00 PM, US Eastern Standard Time on Nov 14, 2023 Tillkännagivande • Sep 26
Elite Pharmaceuticals Files Anda with US FDA to Market Opiate Analgesic Product Elite Pharmaceuticals, Inc. announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product. Tillkännagivande • Sep 08
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer Elite Pharmaceuticals, Inc. announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023. Mr. Ward previously served as the Company's Chief Financial Officer from July 2009 through May 2021, and the Company is pleased to have Mr. Ward join the company again as CFO. Mr. Ward has over 30 years of industry experience, most recently as chief financial officer of Mirror Biologics, Inc., a privately held life science company and before that as chief financial officer of Enveric Biosciences, Inc., a publicly traded biotech company. Prior to Mr. Ward's initial tenure with the Company, Mr. Ward filled multiple finance and supply chain leadership roles with the Actavis Group and its U.S. subsidiary, Amide Pharmaceutical, Inc. and was also a consultant for Centennial Communications Corp., a Nasdaq-listed wireless communications provider where he was engaged in improving internal controls and supporting Sarbanes-Oxley compliance. Mr. Ward began his career as a certified public accountant in the audit department of KPMG and holds a Bachelor of Science degree in accounting from Long Island University in Brooklyn, N.Y, graduating summa cum laude. Tillkännagivande • Aug 29
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study Elite Pharmaceuticals, Inc. engaged in the development, manufacture, and distribution of niche generic products, reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called CNS stimulants. IQVIA reported annual sales for the twelve months ending June 2023 of $5.1 billion for the brand and generic market for this product. The studies were open-label, randomized, balanced, single oral dose, two-treatment, two-period, two sequence, two-way crossover comparative bioavailability studies in healthy, adult, human subjects under fed and fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration. Tillkännagivande • Aug 10
Elite Pharmaceuticals, Inc. to Report Q1, 2024 Results on Aug 14, 2023 Elite Pharmaceuticals, Inc. announced that they will report Q1, 2024 results on Aug 14, 2023 Tillkännagivande • Jun 23
Elite Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Jun 29, 2023 Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Jun 29, 2023 Tillkännagivande • May 04
Elite Pharmaceuticals, Inc Appoints Mark Pellegrino as its Chief Financial Officer Elite Pharmaceuticals, Inc. announced the appointment of Mark Pellegrino as its Chief Financial Officer (CFO), effective May 1, 2023. Pellegrino joins Elite with more than 30 years of experience in financial and operational leadership, primarily in the life sciences sector, including manufacturing and distribution. Pellegrino served for nearly a decade as Senior Director of Finance and Administration at Kedrion Biopharma, Inc., the U.S. division of a multi-national company. Pellegrino also served as CFO for Digital Products, Inc. and spent fifteen years as Vice President of Finance for Romaco, Inc. He most recently held a position at Barbera & Barbera as a consultant in finance and tax. Pellegrino brings a wealth of diversified leadership in corporate operations, corporate finance, and accounting for private and public companies. Tillkännagivande • Feb 09
Elite Pharmaceuticals, Inc. to Report Q3, 2023 Results on Feb 14, 2023 Elite Pharmaceuticals, Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 14, 2023 Tillkännagivande • Feb 08
Elite Pharmaceuticals Reports Positive Results from A Pivotal Bioequivalence Study Elite Pharmaceuticals, Inc. reported positive results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product. The studies were open label, single-dose crossover comparative bioavailability studies in volunteers of male and female patients who were already on established drug regimens under fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration. Tillkännagivande • Nov 09
Elite Pharmaceuticals, Inc. to Report Q2, 2023 Results on Nov 14, 2022 Elite Pharmaceuticals, Inc. announced that they will report Q2, 2023 results on Nov 14, 2022 Tillkännagivande • Sep 08
Elite Pharmaceuticals, Inc. Appoints Kirko Kirkov as Chief Commercial Officer On September 5, 2022, Elite Pharmaceuticals, Inc. entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022. Mr. Kirkov joins Elite as an accomplished and multi-faceted leader with more than twenty years of in-depth business development skills across international pharmaceutical organizations. Before joining the Registrant, Mr. Kirkov served as General Manager of Vertice Pharma, a specialty generics pharmaceutical company, from February 2020 to present. From April 2008 to February 2020, Mr. Kirkov was employed by Sandoz and served in positions of increasing responsibilities beginning with Country Head & Managing Director of Bulgaria from 2008 to 2011. From 2011 to 2013, Mr. Kirkov served as Sandoz’s Business Unit Head, Branded Prescription Generics in Russia, and most recently, from January 2013 to February 2020, served as Sandoz’s Executive Director, Commercial Operations. Mr. Kirkov brings with him a broad range of experience in the areas of business development, operationalization of commercial strategy, and implementation of retail and wholesale channel sales operations, having overseen sales portfolios consisting of 400+ product families, and 1500+ SKUs covering both generic and branded products. Mr. Kirkov has a Bachelor of Science in Mechanical Engineering /Engineering Management from the University of Ottawa, two Masters of Science degrees respectively in Naval Architecture and Ocean Systems Management from the Massachusetts Institute of Technology, a Masters of Science in Applied Positive Psychology and Coaching from the University of East London, and an MBA from the University of Durham. Mr. Kirkov joins Elite in a newly created position to oversee the sale and marketing of commercial products not under license under Elite’s label. Tillkännagivande • Aug 12
Elite Pharmaceuticals, Inc. to Report Q1, 2023 Results on Aug 15, 2022 Elite Pharmaceuticals, Inc. announced that they will report Q1, 2023 results on Aug 15, 2022 Tillkännagivande • Jun 24
Elite Pharmaceuticals, Inc. to Report Fiscal Year 2022 Results on Jun 29, 2022 Elite Pharmaceuticals, Inc. announced that they will report fiscal year 2022 results on Jun 29, 2022 Tillkännagivande • May 12
Elite Pharmaceuticals, Inc. Announces the Appointment of Robert Chen, CPA/MPA, as Chief Financial Officer, Effective May 16, 2022, Succeeding Marc Bregman Elite Pharmaceuticals, Inc. announced the appointment of Robert Chen, CPA/MPA, as its Chief Financial Officer, effective May 16, 2022, succeeding Marc Bregman. Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations. Mr. Chen brings with him extensive and diversified financial leadership background in the areas of financial reporting, including manufacturing, financial and cost accounting, SEC, GAAP and IFRS, as well as financial planning and analysis. Mr. Chen previously served in roles as CFO, Vice President of Finance, and Corporate Controller primarily in the life sciences sector. Mr. Chen most recently served as Vice President of Finance for KBP Biosciences, a clinical-stage biotech start-up. Mr. Chen also held financial positions with Bradley Pharmaceuticals, Novartis, Victory Commercial Management, Medimetriks Pharmaceuticals, and Taiho Oncology. Tillkännagivande • Feb 10
Elite Pharmaceuticals, Inc. to Report Q3, 2022 Results on Feb 14, 2022 Elite Pharmaceuticals, Inc. announced that they will report Q3, 2022 results on Feb 14, 2022 Tillkännagivande • Feb 11
Elite Pharmaceuticals, Inc. to Report Q3, 2021 Results on Feb 16, 2021 Elite Pharmaceuticals, Inc. announced that they will report Q3, 2021 results on Feb 16, 2021 Tillkännagivande • Nov 12
Elite Pharmaceuticals, Inc. to Report Q2, 2021 Results on Nov 16, 2020 Elite Pharmaceuticals, Inc. announced that they will report Q2, 2021 results at 8:40 PM, GMT Standard Time on Nov 16, 2020 Tillkännagivande • Aug 13
Elite Pharmaceuticals, Inc. to Report Q1, 2021 Results on Aug 14, 2020 Elite Pharmaceuticals, Inc. announced that they will report Q1, 2021 results at 8:40 PM, GMT Standard Time on Aug 14, 2020 
